Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) breached their fiduciary duties to shareholders.
If you currently own Acadia stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Acadia Healthcare Company, Inc. (NasdaqGS: ACHC).On September 27, 2024, the Company disclosed the receipt of a voluntary request for information from the U. S. Attorney's Office for the Southern District of New York as well as a grand jury subpoena from the United States District Court.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) breached their fiduciary duties to shareholders.
If you currently own Acadia stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
BlackRock Inc. bought a new position in Acadia Healthcare Company, Inc. (NASDAQ:ACHC – Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 14,957,168 shares of the company’s stock, valued at approximately $441,685,000. BlackRock Inc. owned 16.07% of Acadia Healthcare as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Acadia Healthcare in the first quarter worth about $1,600,000. Goldman Sachs Group Inc. boosted its holdings in Acadia Healthcare by 21.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 698,225 shares of the company’s stock valued at $21,170,000 after acquiring an additional 121,444 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Acadia Healthcare by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 340,916 shares of the company’s stock valued at $10,337,000 after acquiring an additional 27,207 shares during the period. American Century Companies Inc. grew its position in Acadia Healthcare by 531.5% during the 2nd quarter. American Century Companies Inc. now owns 105,739 shares of the company’s stock worth $2,399,000 after acquiring an additional 88,995 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in Acadia Healthcare by 21.9% in the 2nd quarter. Prudential Financial Inc. now owns 9,903 shares of the company’s stock worth $225,000 after purchasing an additional 1,780 shares during the period.
Acadia Healthcare Price Performance Shares of Acadia Healthcare stock opened at $29.87 on Wednesday. The business has a 50 day moving average of $30.14 and a 200 day moving average of $25.81. Acadia Healthcare Company, Inc. has a 52 week low of $11.43 and a 52 week high of $35.83. The company has a market cap of $2.78 billion, a PE ratio of -2.40, a P/E/G ratio of 9.25 and a beta of 0.64. The company has a quick ratio of 1.57, a current ratio of 1.57 and a debt-to-equity ratio of 1.20.
Acadia Healthcare (NASDAQ:ACHC – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.03. Acadia Healthcare had a negative net margin of 33.44% and a positive return on equity of 6.19%. The business had revenue of $865.84 million for the quarter, compared to the consensus estimate of $844.19 million. During the same period in the previous year, the firm earned $0.83 EPS. The company’s quarterly revenue was down .4% compared to the same quarter last year. Acadia Healthcare has set its FY 2026 guidance at 1.450-1.600 EPS. As a group, equities research analysts forecast that Acadia Healthcare Company, Inc. will post 1.55 earnings per share for the current year. Wall Street Analysts Forecast Growth Several research analysts have recently issued reports on ACHC shares. Weiss Ratings restated a “sell (d)” rating on shares of Acadia Healthcare in a report on Friday, June 12th. TD Cowen upped their price target on shares of Acadia Healthcare from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Royal Bank Of Canada increased their price target on shares of Acadia Healthcare from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Monday, May 4th. Jefferies Financial Group raised shares of Acadia Healthcare from a “hold” rating to a “buy” rating and raised their price target for the stock from $24.50 to $30.00 in a report on Wednesday, June 3rd. Finally, UBS Group upped their price objective on shares of Acadia Healthcare from $31.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Acadia Healthcare currently has a consensus rating of “Hold” and an average target price of $29.85.
Check Out Our Latest Research Report on ACHC
(Free Report)
Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.
Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.
Read More Five stocks we like better than Acadia Healthcare Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding ACHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acadia Healthcare Company, Inc. (NASDAQ:ACHC – Free Report).
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
A month has gone by since the last earnings report for Acadia Healthcare (ACHC - Free Report) . Shares have added about 11.8% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Acadia Healthcare due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Acadia Healthcare Company, Inc. before we dive into how investors and analysts have reacted as of late.
Acadia Healthcare Q2 Earnings Beat Estimates on Higher Admissions
Acadia Healthcare reported adjusted second-quarter earnings of 38 cents per share, which beat the Zacks Consensus Estimate by 15.2%. However, the bottom line declined 54% year over year.
Total revenues declined 0.4% year over year to $865.8 million. The top line surpassed the Zacks Consensus Estimate by 2.5%.
The better-than-expected quarterly results reflected strong patient demand, as admissions increased and same-facility patient days improved. Residential Treatment Facilities also delivered double-digit revenue growth. However, lower revenue per patient day, a shorter average length of stay and higher operating expenses weighed on profitability.
ACHC’s Q2 OperationsAcute Inpatient Psychiatric Facilities revenues totaled $494.6 million, which remained flat year over year but beat the Zacks Consensus Estimate by 4.3%.
Specialty Treatment Facilities' revenues declined 8.4% year over year to $133.5 million. Comprehensive Treatment Facilities revenues amounted to $141.2 million, flat year over year. Residential Treatment Facilities revenues increased 11.6% to $96.5 million.
Same-facility revenues of $856.4 million edged down 0.1% year over year but beat the Zacks Consensus Estimate by 3.6%. Patient days increased 0.8%, while revenue per patient day declined 0.8%. Admissions grew 6.4% year over year. The average length of stay decreased 5.3% year over year and missed the consensus estimate by 3.2%.
Overall facility patient days remained flat year over year, while admissions increased 6.3%. Revenue per patient day declined 0.4% year over year, and the average length of stay decreased 5.9%.
Total operating expenses increased 7.3% year over year to $727.6 million, primarily due to higher salaries, wages and benefits, professional fees, supplies and other operating expenses.
Total adjusted EBITDA declined 26% year over year to $149.2 million.
During the quarter, the company added 240 licensed beds from newly constructed facilities.
ACHC’s Q2 Financial UpdateAcadia Healthcare exited the second quarter with cash and cash equivalents of $171.3 million, which increased from the 2025-end level of $133.2 million. It had remaining borrowing capacity of $669.8 million under its $1 billion revolving credit facility at the end of the second quarter.
Total assets of $5.5 billion increased 0.3% from the 2025-end figure.
Long-term debt amounted to $2.4 billion, which declined from $2.5 billion as of Dec. 31, 2025. The current portion of long-term debt was $32.5 million.
Total equity of $2 billion increased from the 2025-end level of $1.9 billion.
Net cash provided by operating activities totaled $223.6 million in the first six months of 2026 compared with $145.0 million in the prior-year period.
Acadia Healthcare’s Share Repurchase UpdateThe company did not buy back shares in the second quarter of 2026.
Acadia Healthcare’s Revised 2026 OutlookAcadia Healthcare updated its 2026 guidance. The company now expects revenues to be in the range of $3.40-$3.45 billion compared with the previous guidance of $3.37-$3.45 billion. Adjusted EBITDA is now projected to be in the band of $590-$615 million compared with the previous outlook of $580-$615 million. Adjusted EPS is now expected to be $1.45-$1.60 compared with the earlier guidance of $1.35-$1.60.
Management also raised its operating cash flow forecast to $350-$400 million from $285-$325 million. Capital expenditures are now expected to be $235-$255 million, down from the prior guidance of $255-$280 million.
Management previously guided for the addition of 400-600 licensed beds in 2026.
How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -7.71% due to these changes.
VGM ScoresCurrently, Acadia Healthcare has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Acadia Healthcare has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerAcadia Healthcare belongs to the Zacks Medical - Hospital industry. Another stock from the same industry, Community Health Systems (CYH - Free Report) , has gained 7.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Community Health Systems reported revenues of $2.83 billion in the last reported quarter, representing a year-over-year change of -9.8%. EPS of -$0.19 for the same period compares with -$0.05 a year ago.
Community Health Systems is expected to post a loss of $0.22 per share for the current quarter, representing a year-over-year change of -117.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -116.7%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Community Health Systems. Also, the stock has a VGM Score of D.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
, /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Acadia Healthcare Company, Inc. (NasdaqGS: ACHC).
On September 27, 2024, the Company disclosed the receipt of a voluntary request for information from the U. S. Attorney's Office for the Southern District of New York as well as a grand jury subpoena from the United States District Court for the Western District of Missouri "related to its admissions, length of stay and billing practices." Then, on October 30, 2024, the Company disclosed that it had lowered its full-year 2024 revenue outlook to a range of $3.15 to $3.165 billion and its full-year 2024 adjusted EBITDA to a range of $725 to $735 million due in part to slower same-store patient day growth of only 3% in the month of October.
The Company has been sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws. Recently, the court presiding over the case denied the Company's motion to dismiss, allowing the case to move forward.
KSF's investigation is focusing on whether Acadia's officers and/or directors breached their fiduciary duties to Acadia's shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Acadia shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3608 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-achc/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3608
1100 Poydras St., Suite 960
New Orleans, LA 70163
View original content to download multimedia:https://www.prnewswire.com/news-releases/acadia-healthcare-investigation-continued-kahn-swick--foti-llc-continues-to-investigate-the-officers-and-directors-of-acadia-healthcare-company-inc---achc-302857600.html
, /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Acadia Healthcare Company, Inc. (NasdaqGS: ACHC).
On September 27, 2024, the Company disclosed the receipt of a voluntary request for information from the U. S. Attorney's Office for the Southern District of New York as well as a grand jury subpoena from the United States District Court for the Western District of Missouri "related to its admissions, length of stay and billing practices." Then, on October 30, 2024, the Company disclosed that it had lowered its full-year 2024 revenue outlook to a range of $3.15 to $3.165 billion and its full-year 2024 adjusted EBITDA to a range of $725 to $735 million due in part to slower same-store patient day growth of only 3% in the month of October.
The Company has been sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws. Recently, the court presiding over the case denied the Company's motion to dismiss, allowing the case to move forward.
KSF's investigation is focusing on whether Acadia's officers and/or directors breached their fiduciary duties to Acadia's shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Acadia shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3608 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-achc/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3608
1100 Poydras St., Suite 960
New Orleans, LA 70163
Acadia Healthcare is rated BUY, driven by a robust capacity expansion pipeline and strong macro demand for mental health services. ACHC's defensible moat stems from its scale—279 facilities, 12.6k beds—positioning it as the largest independent U.S. behavioral healthcare provider. Forward EV/EBITDA of 8.8x reflects a 30% discount to the sector median and 17% below its five-year average, supporting valuation upside.
Key Takeaways Acadia Healthcare raised 2026 adjusted EBITDA guidance as new facilities exceed expectations.ACHC added 300 beds in the first half of 2026 and remains on track for 500-600 beds.Higher expenses are pressuring margins, while ROE and ROIC remain below industry averages. Acadia Healthcare Company, Inc.(ACHC - Free Report) benefits from strong long-term demand for behavioral health services. The company is expanding its network through joint ventures, de novo facilities and bed additions. Shares of ACHC have surged 113.1% year to date, significantly outperforming the industry’s 13.2% growth during the same period.
Acadia Healthcare has a market capitalization of nearly $2.95 billion. However, the stock appears somewhat expensive relative to its industry peers. ACHC is currently trading at a forward 12-month P/E of 18.17X, higher than the industry average of 11.35X, indicating a premium valuation. ACHC currently carries a Zacks Rank #3 (Hold), along with a Value Scoreof C.
Where Do Estimates for ACHC Stand?The consensus mark for 2026 earnings is pegged at $1.54 per share, which has moved up 4 cents over the past 30 days. The consensus estimate for revenues is pegged at $3.43 billion, indicating 3.5% year-over-year growth. ACHC’s bottom line surpassed estimates in each of the trailing four quarters, the average surprise being 47%.
Acadia Healthcare Company, Inc. Price, Consensus and EPS SurpriseFactors Driving ACHC's PerformanceAcadia is making solid progress in ramping up its recently opened facilities, with revenues and facility-level EBITDA from the 2023-2026 facility cohorts exceeding expectations in the second quarter. It remains confident in generating $200 million of incremental adjusted EBITDA compared with 2025 as these facilities mature. Acadia also raised its 2026 adjusted EBITDA guidance to $590-$615 million from $580-$615 million, supporting its outlook for continued earnings growth.
Acadia continues to expand its network through joint ventures, de novos and bed additions. The company added more than 300 beds during the first half of 2026, including 240 licensed beds from newly constructed facilities in the second quarter. Acadia remains on track to add 500-600 beds in 2026, positioning it to capitalize on sustained behavioral healthcare demand.
Net cash provided by operating activities totaled $223.6 million in the first six months of 2026 compared with $145.0 million in the prior-year period. The company ended the quarter with $171.3 million in cash and cash equivalents and $669.8 million available under its revolving credit facility. Its long-term debt-to-capital ratio of 56.7% remains lower than the industry average of 73.2%, reflecting relatively healthy financial positioning. The company expects positive free cash flow generation in the second half of 2026 as capital expenditures decline to an estimated $235-$255 million. Higher operating cash flow and lower CapEx support financial flexibility.
Risk FactorsAcadia Healthcare continues to face elevated operating and legal expenses, which are pressuring profitability. In the second quarter of 2026, total expenses increased to $843.8 million from $819.2 million in the prior-year period due to higher salaries, wages, benefits, supply costs and professional fees.
Operating expenses also rose to 97.5% of revenues from 94.2% a year ago. Total operating expenses included a $28.6 million PLGL reserve adjustment; excluding this adjustment, operating expenses increased 3.1% year over year. These higher costs could continue to pressure Acadia’s margins and profitability.
ACHC’s profitability and capital efficiency metrics remain below industry averages, reflecting slower returns from recent expansion initiatives. The company’s trailing 12-month return on equity (ROE) was 6.2%, significantly below the industry average of 24.8%. Return on invested capital (ROIC) was 5.5%, below the industry average of 9.4%, indicating weaker return generation despite substantial investments, strong cash generation and valuable real estate assets.
Stocks to ConsiderSome better-ranked stocks in the broader Medical space are Tenet Healthcare Corporation (THC - Free Report) and BrightSpring Health Services, Inc. (BTSG - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present, and LifeStance Health Group, Inc. (LFST - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Tenet Healthcare’s 2026 earnings is pegged at $19.85 per share, which has witnessed six upward revisions in the past 30 days, with no movement in the opposite direction. THC beat earnings estimates in each of the trailing four quarters, with the average surprise being 22.7%. The consensus estimate for 2026 revenues is pinned at $22.13 billion, implying 3.9% year-over-year growth.
The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.78 per share, which has witnessed five upward revisions in the past 30 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for 2026 revenues is pinned at $15.24 billion, implying 18.1% year-over-year growth.
The Zacks Consensus Estimate for LifeStance Health’s 2026 earnings is pegged at 15 cents per share, which has witnessed two upward revisions in the past 30 days, with no movement in the opposite direction. LFST beat earnings estimates in each of the trailing four quarters, with the average surprise being 166.67%. The consensus estimate for 2026 revenues is pinned at $1.71 billion, implying 19.7% year-over-year growth.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) breached their fiduciary duties to shareholders.
If you currently own Acadia stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Acadia Healthcare Company, Inc. (NasdaqGS: ACHC). On September 27, 2024, the Company disclosed the receipt of a voluntary request for information from the U. S. Attorney's Office for the Southern District of New York as well as a grand jury subpoena from the United States District Cour.
On August 06, 2026, Acadia Healthcare Co Inc (ACHC) shares fell 4.7% today, closing at $30.73. The stock has exhibited significant volatility over the past year
, /PRNewswire/ -- Robbins LLP reminds investors of their rights following the court's decision to allow securities claims against Acadia Healthcare Company (NASDAQ: ACHC) to proceed.
The case is continuing after the Court denied defendants' motion to dismiss the amended complaint. The ruling means the case can proceed past the motion-to-dismiss stage. It does not determine whether the allegations are true or establish liability. Investors who purchased or otherwise acquired Acadia Healthcare securities during the applicable class period and suffered losses may still have rights in the litigation.
The class action alleges that Acadia Healthcare misled investors concerning its patient admission and detention practices, treatment of patients, and billing practices.
What Does the Court's Decision Mean for Acadia Healthcare Investors?
A motion to dismiss asks the Court to end a lawsuit at an early stage, before the case proceeds through the litigation process.
By denying the motion to dismiss the amended complaint, the Court has allowed the claims to proceed. The ruling does not mean that investors have won the case, nor does it establish that Acadia Healthcare engaged in wrongdoing. Those issues remain to be determined as the litigation proceeds.
For investors who suffered losses in Acadia Healthcare securities, however, the decision means that the litigation remains active and their potential rights have not been extinguished.
What Are the Allegations Against Acadia Healthcare?
According to the amended complaint, defendants made false and/or misleading statements and failed to disclose material information concerning Acadia Healthcare's business practices.
The complaint alleges that Acadia's business model centered on holding vulnerable patients against their will in its facilities, including circumstances in which such detention was allegedly not medically necessary.
The complaint further alleges that:
patients at Acadia Healthcare facilities were subjected to abuse; Acadia allegedly deceived insurance providers into paying for patient stays that were not medically necessary; and Acadia's public statements concerning its business and operations were materially false or misleading because they allegedly failed to disclose these practices and related risks. How Did the Allegations Become Public?
According to the complaint, information concerning Acadia's alleged practices emerged through investigative reporting and subsequent disclosures concerning government inquiries.
On September 1, 2024, The New York Times published an investigative article titled "How a Leading Chain of Psychiatric Hospitals Traps Patients." The article reported allegations concerning Acadia's patient admission and detention practices and detailed individual patient experiences.
Following publication of the article, Acadia Healthcare's stock price fell $3.72 per share, or approximately 4.5%, to close at $78.21 per share on September 3, 2024, according to the complaint.
Then, on September 27, 2024, Acadia disclosed that it had received a voluntary request for information from the United States Attorney's Office for the Southern District of New York and a grand jury subpoena from the United States District Court for the Western District of Missouri concerning its admissions, length-of-stay, and billing practices.
Following that disclosure, Acadia's stock price fell $12.38 per share, or approximately 6.36%, to close at $63.28 per share on September 27, 2024, according to the complaint.
What Does This Mean for Shareholders?
The denial of the motion to dismiss means the securities class action continues. If the class action settles, the Company will incur expenses in the form of any payout to shareholders, as well as fees and expenses.
Investors who have questions about their rights may contact Robbins LLP for more information.
Frequently Asked Questions
Did Acadia Healthcare's motion to dismiss get denied?
Yes. The Court denied defendants' motion to dismiss the amended complaint, allowing the securities class action to proceed.
Does the ruling mean Acadia Healthcare lost the case?
No. The Court's decision is not a finding that Acadia Healthcare violated the securities laws or that the allegations are true. It means the claims survived the motion-to-dismiss stage and the litigation can continue.
Do Acadia Healthcare shareholders still have rights?
Yes. Investors who fall within the applicable class definition and suffered losses may still have rights in the litigation. The denial of the motion to dismiss means the case remains active.
What is the Acadia Healthcare class action about?
The lawsuit alleges that Acadia Healthcare failed to disclose material information concerning alleged patient detention practices, alleged patient abuse, and alleged insurance billing practices.
Does it cost anything to participate?
Robbins LLP represents investors on a contingency fee basis. Investors never pay attorneys' fees or litigation expenses. If there is a recovery in favor of shareholders, defendants will pay attorneys' fees and expenses.
Contact Robbins LLP
Investors seeking information about the Acadia Healthcare securities class action and their rights may submit an inquiry through Robbins LLP's website, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
About Robbins LLP
Robbins LLP is a shareholder rights law firm representing investors in securities fraud and shareholder litigation. The firm has helped recover more than $1 billion for shareholders, secured significant corporate governance reforms at more than 400 Fortune 1000 companies, and has extensive experience prosecuting securities class actions nationwide.
"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.
To be notified if a class action against Acadia Healthcare Company settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Key Takeaways Acadia Healthcare beat Q2 earnings and revenue estimates despite lower profit and a slight revenue decline.ACHC raised 2026 revenue, adjusted EBITDA, EPS and operating cash flow guidance while lowering capex.Acadia Healthcare saw higher admissions and added 240 licensed beds, despite lower revenue per patient day. Acadia Healthcare Company, Inc. (ACHC - Free Report) reported adjusted second-quarter earnings of 38 cents per share, which beat the Zacks Consensus Estimate by 15.2%. However, the bottom line declined 54% year over year.
Total revenues declined 0.4% year over year to $865.8 million. The top line surpassed the Zacks Consensus Estimate by 2.5%.
The better-than-expected quarterly results reflected strong patient demand, as admissions increased and same-facility patient days improved. Residential Treatment Facilities also delivered double-digit revenue growth. However, lower revenue per patient day, a shorter average length of stay and higher operating expenses weighed on profitability.
Acadia Healthcare Company, Inc. Price, Consensus and EPS SurpriseACHC’s Q2 OperationsAcute Inpatient Psychiatric Facilities revenues totaled $494.6 million, which remained flat year over year but beat the Zacks Consensus Estimate by 4.3%.
Specialty Treatment Facilities' revenues declined 8.4% year over year to $133.5 million. Comprehensive Treatment Facilities revenues amounted to $141.2 million, flat year over year. Residential Treatment Facilities revenues increased 11.6% to $96.5 million.
Same-facility revenues of $856.4 million edged down 0.1% year over year but beat the Zacks Consensus Estimate by 3.6%. Patient days increased 0.8%, while revenue per patient day declined 0.8%. Admissions grew 6.4% year over year. The average length of stay decreased 5.3% year over year and missed the consensus estimate by 3.2%.
Overall facility patient days remained flat year over year, while admissions increased 6.3%. Revenue per patient day declined 0.4% year over year, and the average length of stay decreased 5.9%.
Total operating expenses increased 7.3% year over year to $727.6 million, primarily due to higher salaries, wages and benefits, professional fees, supplies and other operating expenses.
Total adjusted EBITDA declined 26% year over year to $149.2 million.
During the quarter, the company added 240 licensed beds from newly constructed facilities.
ACHC’s Q2 Financial UpdateAcadia Healthcare exited the second quarter with cash and cash equivalents of $171.3 million, which increased from the 2025-end level of $133.2 million. It had remaining borrowing capacity of $669.8 million under its $1 billion revolving credit facility at the end of the second quarter.
Total assets of $5.5 billion increased 0.3% from the 2025-end figure.
Long-term debt amounted to $2.4 billion, which declined from $2.5 billion as of Dec. 31, 2025. The current portion of long-term debt was $32.5 million.
Total equity of $2 billion increased from the 2025-end level of $1.9 billion.
Net cash provided by operating activities totaled $223.6 million in the first six months of 2026 compared with $145.0 million in the prior-year period.
Acadia Healthcare’s Share Repurchase UpdateThe company did not buy back shares in the second quarter of 2026.
Acadia Healthcare’s Revised 2026 OutlookAcadia Healthcare updated its 2026 guidance. The company now expects revenues to be in the range of $3.40-$3.45 billion compared with the previous guidance of $3.37-$3.45 billion. Adjusted EBITDA is now projected to be in the band of $590-$615 million compared with the previous outlook of $580-$615 million. Adjusted EPS is now expected to be $1.45-$1.60 compared with the earlier guidance of $1.35-$1.60.
Management also raised its operating cash flow forecast to $350-$400 million from $285-$325 million. Capital expenditures are now expected to be $235-$255 million, down from the prior guidance of $255-$280 million.
Management previously guided for the addition of 400-600 licensed beds in 2026.
ACHC’s Zacks RankAcadia Healthcare currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
How Did Other Medical Companies Perform?Here are some stocks from the broader Medical space that have also reported their quarterly results: Tenet Healthcare Corporation (THC - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Universal Health Services, Inc. (UHS - Free Report) . Here's how they have performed:
Tenet Healthcare reported second-quarter 2026 adjusted earnings per share of $6.12, which surpassed the Zacks Consensus Estimate by 50%. The bottom line increased 52.2% year over year. THC’s net operating revenues advanced 6.8% year over year to $5.63 billion. The top line surpassed the consensus mark by 4.4%. The quarterly results were driven by strong same-facility revenue growth, higher patient acuity, disciplined expense management and higher Medicaid supplemental revenues. However, the gains were partly offset by an unfavorable payer mix due to lower exchange admissions.
UnitedHealth Group reported second-quarter 2026 adjusted earnings per share of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year. Revenues rose 0.4% year over year to $112 billion. The top line beat the consensus mark by 1.7%. UNH’s strong quarterly results were aided by growth in commercial fee-based membership and the strength in Optum Insight. Medical cost management, pricing discipline and benefit design changes also contributed to the upside. However, weaker performance at Optum Health and Optum Rx, along with declining risk-based membership, partially offset these gains.
Universal Health Services reported second-quarter 2026 adjusted earnings per share of $5.98, which beat the Zacks Consensus Estimate by 5.7%. The bottom line rose 10.1% year over year. Net revenues of $4.6 billion improved 8.3% year over year. The top line beat the consensus mark by 2.6%. UHS’ strong quarterly results were driven by healthy revenue growth across both the Acute Care and Behavioral Health segments. Higher adjusted admissions, increased patient days and improved unit revenues on a same-facility basis supported performance in both businesses. However, the upside was partly offset by elevated operating costs.
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"Acadia Healthcare NASDAQ: ACHC reported second-quarter 2026 results that management said were in line with expectations, supported by progress at recently opened facilities, disciplined spending and strong free cash flow generation.
Get Acadia Healthcare alerts:
Revenue totaled $866 million, unchanged from the prior-year quarter. The comparison was affected by supplemental payment programs: second-quarter 2025 included $48.7 million from Tennessee payments related to prior periods, while the latest quarter included $22.3 million from Florida payments related to the 2025 program year. Excluding those items, revenue would have increased 2.8% year over year, according to Interim Chief Financial Officer David Duckworth.
Adjusted EBITDA was $149.2 million. The result included a $26.1 million benefit from Florida supplemental payments, offset by a $28.6 million actuarial adjustment increasing professional and general liability reserves for prior-year cases. Together, those items reduced adjusted EBITDA by $2.5 million relative to the company’s April guidance, Duckworth said.
Same-Facility Trends and Service Lines Same-facility revenue was flat year over year, as a 0.8% increase in patient days was offset by a 0.8% decline in revenue per patient day. After adjusting for the Florida and Tennessee supplemental payments related to prior periods, same-facility revenue growth would have been 3.2%.
Duckworth said changes to New York’s Medicaid program affected Acadia’s Pennsylvania facilities and reduced same-facility revenue growth by about 1 percentage point. The company said it has been working to expand referral sources in Pennsylvania and other states.
Acute care: Revenue was $495 million, flat year over year but up 6% after normalizing for supplemental payments. Management cited strong volumes and admissions at existing acute facilities as well as newer joint-venture and de novo locations. Specialty care: Revenue was $134 million, up 4% sequentially from the first quarter. The business experienced the full-quarter impact of the New York Medicaid decision. Residential treatment centers: Revenue rose 12% year over year to $97 million, driven by volume growth and higher revenue per day. Comprehensive treatment centers: Revenue was $141 million, flat year over year. Acadia opened two CTC clinics during the quarter and said it continues to see demand for opioid-treatment services, although the segment performed slightly below its expectations. Chief Executive Officer Debbie Osteen said Acadia’s facilities opened between 2023 and 2026 generated revenue and facility-level EBITDA ahead of management’s expectations during the quarter. The company continues to target $200 million of incremental adjusted EBITDA from that group of facilities relative to 2025.
Osteen pointed to Coachella Valley, a 2024 de novo facility, as an example of the ramp-up progress. The facility is above 90% occupancy, she said, and Acadia is evaluating additional bed capacity there.
Expansion, Staffing and Cost Controls Acadia opened two acute facilities during the quarter: a 144-bed joint-venture facility with Orlando Health in Florida and a 96-bed joint-venture facility with Methodist Jennie Edmundson in Iowa. The company added more than 300 beds in the first half and remains on track to add 500 to 600 beds in 2026, including a planned de novo acute-facility opening near Jacksonville, Florida, in the third quarter.
Management said it has shortened timelines for licensing, accreditation and payer contracting at new facilities. Osteen also cited closer communication with joint-venture partners and greater expense discipline as factors helping new sites ramp more quickly.
Start-up facility losses were $12 million in the second quarter, better than management expected, although Duckworth said losses could rise to roughly $12 million to $14 million in the third quarter because of recent and planned openings. He said the company expects the amount to decline below $12 million in the fourth quarter as facilities mature.
Duckworth said the labor market remained stable, with wage-cost growth running around 3% overall, though results vary by role and geography. Acadia also reported that corporate overhead declined by about $3 million from the first quarter and was flat year over year.
Cash Flow, Debt Reduction and Updated Outlook Operating cash flow was $162 million in the second quarter, while capital expenditures were $39 million, resulting in free cash flow of $124 million. Acadia repaid $113 million of debt and ended the quarter with $171 million in cash and cash equivalents. Its net leverage ratio was approximately 4.1 times adjusted EBITDA as of June 30.
The company revised its full-year capital-expenditure forecast to $235 million to $255 million, including $120 million to $140 million expected in the second half. Duckworth said the revision reflects the timing of projects and a more disciplined approach to capital deployment. Acadia expects positive free cash flow in the second half.
For 2026, Acadia updated its outlook to:
Revenue of $3.4 billion to $3.45 billion; Adjusted EBITDA of $590 million to $615 million; Adjusted earnings per share of $1.45 to $1.60; and Operating cash flow of $350 million to $400 million. The guidance does not fully include potential expansion of supplemental payment programs. Duckworth said Florida and Ohio programs under regulatory review for the 2026 program year could add more than $20 million in incremental EBITDA, while the company included a $5 million historical baseline amount for Florida in its third-quarter expectations.
On liability reserves, Duckworth said the $28.6 million second-quarter adjustment was primarily tied to prior-year cases from the 2025 policy year moving toward settlement. He said reserves for the current year remain consistent with prior expectations of $100 million to $110 million, while the inclusion of the prior-year adjustment puts the total annual amount in a range of roughly $130 million to $135 million.
About Acadia Healthcare (NASDAQ:ACHC)Acadia Healthcare Company, Inc NASDAQ: ACHC is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.
Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Acadia Healthcare Right Now?Before you consider Acadia Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acadia Healthcare wasn't on the list.
While Acadia Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Results Revenue totaled $865.8 million, which was approximately flat compared with the second quarter of 2025. As described on page 2, total revenue growth in the second quarter was 2.8%1 after normalizing for prior period supplemental payment program revenue in each of the respective quarte.
Acadia Healthcare (ACHC - Free Report) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.83 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +15.15%. A quarter ago, it was expected that this provider of inpatient behavioral health care services would post earnings of $0.28 per share when it actually produced earnings of $0.37, delivering a surprise of +32.14%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Acadia Healthcare, which belongs to the Zacks Medical - Hospital industry, posted revenues of $865.84 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.50%. This compares to year-ago revenues of $869.23 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia Healthcare shares have added about 129% since the beginning of the year versus the S&P 500's gain of 8.3%.
What's Next for Acadia Healthcare?While Acadia Healthcare has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia Healthcare was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.50 on $871.47 million in revenues for the coming quarter and $1.50 on $3.4 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Hospital is currently in the bottom 12% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Foghorn Therapeutics Inc. (FHTX - Free Report) , another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended June 2026.
This company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of +17.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Foghorn Therapeutics Inc.'s revenues are expected to be $8.12 million, up 7.4% from the year-ago quarter.
SAN DIEGO, July 28, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors of their rights following the court's decision to allow securities claims against Acadia Healthcare Company (NASDAQ: ACHC) to proceed. The case is continuing after the Court denied defendants' motion to dismiss the amended complaint.
SAN DIEGO--(BUSINESS WIRE)---- $ACHC #Medicine--Robbins LLP reminds investors of their rights following the court's decision to allow securities claims against Acadia Healthcare Company (NASDAQ: ACHC) to proceed.The case is continuing after the Court denied defendants' motion to dismiss the amended complaint. The ruling means the case can proceed past the motion-to-dismiss stage. It does not determine whether the allegations are true or establish liability. Investors who purchased or otherwise acquired Acadia Healt.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the market. Acadia will host a conference call with institutional investors and analysts on Wednesday, July 29, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website, and the archived webcast will be availabl.
The Zacks Medical-Hospital industry is undergoing a structural transformation as patients and payers increasingly shift toward lower-cost care settings outside traditional hospitals. As a result, the fastest growth is coming from ambulatory surgery centers, home health and post-acute care providers. Meanwhile, hospitals continue to contend with elevated patient utilization, persistent labor and supply cost inflation, and reimbursement and regulatory uncertainty. To protect margins, providers are accelerating investments in AI, revenue cycle management and digital technologies, while streamlining operations and expanding outpatient care networks.
Strategic mergers and acquisitions also remain an important growth lever to expand scale, improve efficiency and strengthen market presence. Companies like Tenet Healthcare Corporation (THC - Free Report) , Universal Health Services, Inc. (UHS - Free Report) , Acadia Healthcare Company, Inc. (ACHC - Free Report) and Community Health Systems, Inc. (CYH - Free Report) are streamlining operations, strengthening cost discipline and investing in higher-growth service lines.
Industry Overview The Zacks Medical-Hospital industry comprises for-profit hospital companies that provide healthcare through different types of hospitals, including acute care, outpatient, rehabilitation and psychiatric. These entities are engaged in internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, telehealth, mental health and diagnostic and emergency services. Revenues of these companies depend on inpatient occupancy, medical and ancillary services ordered by physicians and provided to patients, and the volume of ambulatory surgery centers’ (ASC) procedures. These companies receive payments for patient services from the government under the Medicare program, Medicaid, or similar programs, managed care plans (including plans offered through the American Health Benefit Exchanges), private insurers and directly from patients.
4 Key Trends Shaping the Hospital Industry Demand Grows as Care Moves Beyond Hospitals: Demand for healthcare continues to rise, supported by an aging U.S. population, increasing chronic disease prevalence and higher use of elective procedures. CMS projects national health spending to climb steadily and reach around $9 trillion by 2034, making up 20.6% of the economy. Meanwhile, care is shifting away from traditional inpatient hospitals toward ambulatory surgery centers, outpatient clinics, home health and virtual care. Lower-cost settings are becoming more attractive for patients and payers, prompting hospital systems to expand outpatient networks, strengthen physician partnerships and invest in home-based services to meet changing demand while improving asset utilization.
Margin Pressure Keeps Efficiency in Focus: Hospitals continue to face elevated labor, supply and pharmaceutical costs, even as contract staffing expenses ease from pandemic highs. Reimbursement growth has generally lagged cost inflation, keeping pressure on operating margins. Additionally, emerging cyber risks are pushing up insurance premiums and compliance costs, adding further pressure across the system. In response, providers are tightening cost controls, improving workforce productivity and automating administrative tasks. Many are also using data analytics to optimize staffing, purchasing and patient flow.
Technology Becomes a Competitive Advantage: Artificial intelligence is moving beyond pilot programs and becoming part of everyday hospital operations. It is increasingly improving revenue cycle management, prior authorization workflows and clinical documentation, helping providers accelerate collections and reduce administrative workload. Digital tools are also strengthening patient engagement through online scheduling, remote monitoring and virtual follow-up care. Telehealth remains an important part of care delivery, particularly for rural communities and patients with chronic conditions, allowing hospitals to extend services beyond their physical campuses while improving continuity of care.
Strategic Expansion Strengthens Market Position: Hospitals continue to pursue mergers, acquisitions and strategic partnerships to improve scale, expand specialty services and strengthen financial stability. While regulatory scrutiny has slowed some large hospital mergers, providers remain active in acquiring physician practices, outpatient facilities and complementary care businesses. These investments broaden referral networks, support the shift toward lower-cost care settings and create opportunities for greater operating efficiency. Larger health systems are also investing in digital infrastructure and outpatient capacity, positioning themselves to compete more effectively as healthcare delivery continues to evolve.
Zacks Industry Rank Indicates Positive Outlook The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all member stocks, signals promising near-term prospects. The Zacks Medical-Hospital industry, which is housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #107, which places it in the top 43% of nearly 250 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
Looking at the aggregate earnings estimate revisions, it appears that analysts are becoming optimistic about this group’s earnings growth potential. As a matter of fact, the industry’s earnings estimates for 2026 have gone up by 5.7% over the past year.
Considering the encouraging dynamics of the industry, we will present a few stocks that should be on your watchlist. But it’s worth taking a look at the industry’s shareholder returns and current valuation first.
Industry Lags Sector and S&P 500 The Zacks Medical-Hospital industry has fared worse than the broader Zacks Medical sector and the Zacks S&P 500 Composite over the past year, pressured by concerns over reimbursement, healthcare policy uncertainty and a shift in investor preference toward higher-growth technology and AI stocks.
The industry has declined 6.9% over the past year compared with a 6.9% gain for the broader sector and a 22.5% advance for the S&P 500.
One-Year Price PerformanceIndustry's Current Valuation Since hospital operators are capital-intensive businesses that require significant investment in facilities and equipment, it makes sense to value them based on the EV/EBITDA (Enterprise Value/ Earnings before Interest Tax Depreciation and Amortization) ratio. On the basis of the trailing 12-month EV/EBITDA ratio, the industry trades at 6.60X compared with the S&P 500’s 18.23X and the sector’s 9.94X.
Over the past five years, the industry has traded as high as 10.66X and as low as 6.34X, with a median of 8.33X, as the charts below show.
EV/EBITDA Ratio (Past 5 Years)
4 Hospital Stocks to Watch Tenet Healthcare: Based in Dallas, TX, the company operates acute care hospitals and is one of the nation's largest ambulatory care platforms. It continues to expand its Ambulatory Care segment through strategic acquisitions to capitalize on growing demand for outpatient procedures. The company is also benefiting from solid same-facility revenue growth, higher adjusted admissions and sustained momentum across its key service lines.
The Zacks Consensus Estimate for Tenet Healthcare’s 2026 bottom line is pegged at $17.61 per share, up 5% year over year. The same for 2027 indicates further growth to $17.63 per share. It beat earnings estimates in each of the past four quarters, with an average surprise of 20.6%. The consensus mark for 2026 and 2027 revenues indicates 3.3% and 1.9% year-over-year growth, respectively. Shares of the company have gained 1.6% over the past month. It currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Price & Consensus: THC
Universal Health Services: Headquartered in King of Prussia, PA, the company operates acute care hospitals, outpatient centers and one of the nation's largest behavioral health networks. Its services span internal medicine, autism care, addiction treatment and military-related healthcare. Growth is being driven by tuck-in acquisitions, rising patient days and admissions, facility expansion and partnerships that strengthen its behavioral health presence. UHS also maintains a shareholder-friendly capital allocation strategy, with regular buybacks and dividends, and had $1.298 billion remaining under its share repurchase authorization as of March 31, 2026.
The Zacks Consensus Estimate for Universal Health’s 2026 and 2027 bottom line is pegged at $23.47 and $25.40 per share, up 8% and 8.2% year over year, respectively. It beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 9.5%. The consensus mark for 2026 and 2027 revenues indicates 6.8% and 5.1% year-over-year increases, respectively. While Universal Health shares have declined 6.4% over the past month, improving operations are expected to support a future rebound. It also currently has a Zacks Rank #3.
Price & Consensus: UHS
Acadia Healthcare: Based in Franklin, TN, it operates Acute Inpatient Psychiatric Facilities and Comprehensive Treatment Centers, which remain its core growth engines. Rising patient days, revenues per patient day, higher admissions and strong demand for mental health and substance use treatment continue to support steady long-term growth. ACHC’s solid cash generation ability and meaningful real estate assets provide financial flexibility and downside support. Following operational challenges over the past year, management's strategic initiatives are expected to improve execution and support earnings recovery.
The Zacks Consensus Estimate for Acadia Healthcare’s 2026 bottom line is pegged at $1.50 per share. The same for 2027 indicates a 14.8% year-over-year jump to $1.72 per share. It beat earnings estimates in each of the past four quarters, with an average surprise of 47.5%. The consensus mark for 2026 and 2027 revenues indicates 2.6% and 5.7% year-over-year growth, respectively. ACHC shares have gained 8.9% over the past month. It currently has a Zacks Rank #3.
Price & Consensus: ACHC
Community Health Systems: Headquartered in Franklin, TN, it operates a network of acute care hospitals and outpatient centers. The company is benefiting from lower expenses, higher-acuity procedures, improving commercial payer mixand resilient same-store revenues. Management is also focusing on operational efficiency and selective partnerships to support growth. In parallel, CYH continues to divest non-core assets to sharpen its portfolio, reduce debt burden and improve long-term profitability, even though these moves could pressure results in the near term.
The Zacks Consensus Estimate for Community Health Systems’ 2026 bottom line is pegged at a loss of 58 cents per share. The same for 2027 implies a 71.3% year-over-year improvement. The consensus mark for 2026 and 2027 revenues is pegged at $11.56 billion and $11.67 billion, respectively. Shares of Community Health Systems have jumped 15.9% in the past month. It currently has a Zacks Rank #3.
Key Takeaways ACHC raised full-year Adjusted EBITDA guidance after Q1 2026 revenues rose 7.6% to $828.8 million.ACHC is prioritizing returns from existing assets and plans 2026 capital spending of $255-$280 million.ACHC is resolving disputes, strengthening compliance, and improving retention. Acadia Healthcare Company, Inc. (ACHC - Free Report) demonstrates how a mission-driven healthcare company can create long-term shareholder value. As the largest standalone behavioral health provider in the United States, operating 275 facilities and more than 12,400 beds across 40 states, Acadia plays a critical role in addressing the nation's growing mental health and addiction treatment needs. Following a challenging period marked by regulatory scrutiny and industry-wide pressures, it has focused on rebuilding operational strength and restoring investor confidence.
Over the past year, management has taken meaningful steps to protect shareholder value. Acadia resolved some legacy billing disputes, worked toward strengthening compliance standards and improving workforce retention, and brought back experienced industry leader Debbie Osteen as CEO. These actions signal a commitment to accountability, operational discipline and long-term value creation.
Acadia's strategy has also evolved. Rather than pursuing growth, it has shifted toward maximizing returns from its existing footprint, limiting planned 2026 capital expenditures to a range of $255 million to $280 million. This strategic shift is evident in the company’s recent results, with first-quarter 2026 revenues rising 7.6% year over year to $828.8 million and management raising its full-year adjusted EBITDA guidance from $575-$610 million to $580-$615 million.
Demand for mental health and addiction treatment continues to rise, supported by growing awareness and significant unmet patient needs. While some historical expansions weighed on returns, many recently developed facilities are approaching maturity. Acadia now has an opportunity to convert years of investment into improved profitability, creating a potential turnaround opportunity for long-term investors.
How Are Competitors Faring?Peers such as Universal Health Services, Inc. (UHS - Free Report) and LifeStance Health Group, Inc. (LFST - Free Report) are also pursuing growth and operational efficiency initiatives.
Universal Health Services is increasingly focused on extracting greater value from its behavioral health network. Alongside efforts to improve occupancy and outpatient growth, UHS recently announced its $835 million acquisition of Talkspace to expand patient access and broaden treatment options.
LifeStance Health continues to strengthen its outpatient mental health platform through clinician expansion and technology-enabled care, reflecting LFST’s efforts to capture a bigger share of the growing demand for behavioral health services.
ACHC’s Price Performance, Valuation & EstimatesShares of Acadia have gained 20.9% over the past year compared to the industry’s 8.4% decline over the same period.
Image Source: Zacks Investment Research
From a valuation standpoint, ACHC trades at a forward price-to-earnings ratio of 15.71X, up from the industry average of 8.45X. ACHC carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ACHC’s 2026 earnings is pegged at $1.50 per share, which has moved 1 cent up in the past 60 days.
Image Source: Zacks Investment Research
Acadia currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ACHC rides on strong demand and expansion gains, but premium valuation, rising costs, and weak efficiency raise caution for investors weighing next moves.
The Zacks Medical-Hospital industry is in the middle of a major shift as patients and payers push for cheaper care outside traditional hospitals. As a result, the fastest growth is now coming from ambulatory centers and post-acute care providers. However, hospitals still face pressure from rising utilization, higher labor and supply costs, and regulatory uncertainty. To respond, providers are investing in AI and technology upgrades, tightening cost structures and expanding services into lower-cost care settings. Mergers and acquisitions also remain a key strategy, helping companies gain scale, cut costs and expand their reach in a fragmented market. Leaders like Tenet Healthcare Corporation (THC - Free Report) , Universal Health Services, Inc. (UHS - Free Report) , Acadia Healthcare Company, Inc. (ACHC - Free Report) and Community Health Systems, Inc. (CYH - Free Report) are responding by improving efficiency, tightening spending and focusing on selective growth opportunities.
Industry Overview The Zacks Medical-Hospital industry comprises for-profit hospital companies that provide healthcare through different types of hospitals, including acute care, outpatient, rehabilitation and psychiatric. These entities are engaged in internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics, and obstetrics, telehealth, mental health and diagnostic and emergency services. Revenues of these companies depend on inpatient occupancy, medical and ancillary services ordered by physicians and provided to patients, and the volume of ambulatory surgery centers’ (ASC) procedures. These companies receive payments for patient services from the government under the Medicare program, Medicaid, or similar programs, managed care plans (including plans offered through the American Health Benefit Exchanges), private insurers and directly from patients.
4 Key Trends to Watch in the Hospital Industry Rising Demand, Shifting Care Models: Elective procedures continue to rise, lifting patient volumes and boosting overall utilization. Longer term, an aging U.S. population continues to support steady growth in healthcare demand. National health spending is also climbing, with CMS projecting its share of GDP to rise from 17.6% in 2023 to 20.3% by 2033. Meanwhile, cost pressure and faster tech adoption are pushing more care away from inpatient hospitals and into outpatient clinics, ambulatory centers and even patients’ homes. While this shift can improve convenience and lower costs, it also leaves some hospitals with underused beds and heavy fixed expenses. To adapt, providers are expanding beyond hospital walls through partnerships, home-based services, remote monitoring and preventive care programs.
Efficiency Push to Defend Margins: Hospitals are working through ongoing cost pressure as wages, benefits, and supply expenses remain elevated and unpredictable. At the same time, reimbursement increases have not kept pace with rising operating costs, keeping margins tight. To stay profitable, providers are leaning harder on automation, rethinking staffing models and improving purchasing discipline through vendor renegotiations. Dependence on high-cost contract labor is easing from peak levels, offering some relief. Still, hospitals are facing a new challenge as cyber risks rise, driving up insurance premiums and compliance spending and adding another cost burden across the system.
Tech Adoption Expands Access and Productivity: Hospitals are moving faster on AI, automation, and analytics to cut inefficiencies, support better clinical decisions and reduce administrative workload. These tools are improving care coordination, boosting patient engagement, and helping systems manage costs over time. Telehealth has also become a core part of care delivery, extending hospital reach well beyond the pandemic. It is especially valuable for rural and underserved communities, where virtual visits and remote monitoring can close gaps in access and improve continuity of care.
Scale and Partnerships Drive Stability: Hospital systems are stepping up mergers, acquisitions and partnerships to gain scale, improve efficiency and strengthen financial footing. With the market still highly fragmented, shifting care models and clearer regulatory direction are supporting renewed deal activity. Larger, better-capitalized players are acquiring or backing smaller hospitals under pressure. Partnerships focused on technology, data sharing and new care settings are helping providers expand access, upgrade capabilities and stay competitive in a changing healthcare landscape.
Zacks Industry Rank Indicates Positive Outlook The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all member stocks, signals promising near-term prospects.The Zacks Medical-Hospital industry, which is housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #54, which places it in the top 22% of more than 240 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
Looking at the aggregate earnings estimate revisions, it appears that analysts are becoming optimistic about this group’s earnings growth potential. As a matter of fact, the industry’s earnings estimates for 2026 have gone up by 5.4% over the past year.
Considering the encouraging dynamics of the industry, we will present a few stocks that should be on your watchlist. But it’s worth taking a look at the industry’s shareholder returns and current valuation first.
Industry Lags S&P 500 But Outperforms Sector The Zacks Medical-Hospital industry has fared better than the broader Zacks Medical sector, though it has underperformed the Zacks S&P 500 Composite over the past year.
The industry has gained 22.5% over this period, significantly outperforming the broader sector’s growth of 5.7% but underperforming the S&P 500's appreciation of 33.8%.
One-Year Price Performance
Industry's Current Valuation Since hospital operators are capital-intensive and often carry meaningful leverage, it makes sense to value them based on the EV/EBITDA (Enterprise Value/ Earnings before Interest Tax Depreciation and Amortization) ratio. On the basis of the trailing 12-month EV/EBITDA ratio, the industry trades at 7.06X compared with the S&P 500’s 17.16X and the sector’s 9.10X.
Over the past five years, the industry has traded as high as 10.66X and as low as 7.06X, with a median of 8.37X, as the charts below show.
EV/EBITDA Ratio (Past 5 Years)
4 Hospital Stocks to Watch Community Health Systems: Headquartered in Franklin, TN, it operates a network of acute care hospitals and outpatient centers. The company is benefiting from lower expenses, improving payer mix and higher same-store admissions. Management is also focusing on operational efficiency and selective partnerships to support growth. In parallel, CYH continues to divest non-core assets to sharpen its portfolio and improve long-term profitability, even though these moves could pressure results in the near term.
The Zacks Consensus Estimate for Community Health Systems’ 2026 bottom line has improved 31.1% over the past 60 days. The same for 2027 implies a further 84.1% year-over-year improvement. The consensus mark for 2026 and 2027 revenues is pegged at $11.68 billion and $11.96 billion, respectively. Shares of Community Health Systems have gained 23.3% in the past year. It currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Price & Consensus: CYH
Tenet Healthcare: Based in Dallas, TX, it operates acute care hospitals and a large ambulatory care platform. The company is expanding its Ambulatory Care segment through targeted acquisitions to capture rising demand for outpatient procedures. Tenet is also benefiting from a favorable payer mix, improving same-hospital admissions and patient acuity, and continued growth across key service lines.
The Zacks Consensus Estimate for Tenet Healthcare’s 2026 and 2027 bottom line is pegged at $17.30 and $17.41 per share, up 3.1% and 0.7% year over year, respectively. It beat earnings estimates in each of the past four quarters, with an average surprise of 27%. The consensus mark for 2026 and 2027 revenues indicates 3.2% and 1.9% year-over-year growth, respectively. Shares of the company have gained 57.2% over the past year. It currently has a Zacks Rank #3 (Hold).
Price & Consensus: THC
Universal Health Services: Headquartered in King of Prussia, PA, it operates acute care hospitals, outpatient centers and a large behavioral health network. The company provides treatment across areas such as internal medicine, autism services, addiction recovery and military-related care. Growth is being supported by tuck-in acquisitions, rising patient days, facility expansion, additional licensed beds and partnerships that strengthen its behavioral health footprint. UHS has also consistently returned capital to shareholders through buybacks, repurchasing nearly 36% of shares outstanding since 2019.
The Zacks Consensus Estimate for Universal Health’s 2026 and 2027 bottom line is pegged at $23.43 and $25.52 per share, up 7.8% and 8.9% year over year, respectively. It beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 10.7%. The consensus mark for 2026 and 2027 revenues indicates 6.6% and 5.2% year-over-year increases, respectively. Shares of Universal Health have gained 2.9% over the past year. It currently has a Zacks Rank #3.
Price & Consensus: UHS
Acadia Healthcare: Based in Franklin, TN, itoperates Acute Inpatient Psychiatric Facilities and Comprehensive Treatment Centers, which remain its core growth engines. Rising patient volumes and strong demand for mental health and substance use treatment continue to support steady long-term growth. Still, the stock has declined 9.3% over the past year, pressured by ongoing media scrutiny and investor concerns around management discipline. Even so, ACHC’s solid cash generation and meaningful real estate assets provide financial flexibility and downside support. Combined with management’s recent strategic actions to improve execution and strengthen operations, the company appears positioned for a potential recovery.
The Zacks Consensus Estimate for Acadia Healthcare’s 2026 and 2027 bottom line is pegged at $1.48 and $1.61 per share, down 26% and up 8.7% year over year, respectively. It beat earnings estimates in each of the past four quarters, with an average surprise of 43%. The consensus mark for 2026 and 2027 revenues indicates 3% and 6.2% year-over-year growth, respectively. It currently has a Zacks Rank #3.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its first quarter 2026 results on Wednesday, April 29, 2026, after the close of the market. Acadia will also conduct a conference call with institutional investors and analysts on Thursday, April 30, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
Hedge fund manager David Einhorn said he is focusing on capital protection as markets rally on geopolitical optimism, warning that investors may be underestimating potential downside risks.
"It probably won't surprise anyone that we are again putting capital preservation at the top of our priorities," Einhorn said in his latest investor letter dated Monday and obtained by CNBC. "With so little downside priced in, we are willing to risk missing out on a possible recovery to position ourselves to play more offense, should one of the downside scenarios materialize."
U.S. stocks have rebounded violently with the S&P 500 entirely erasing the losses suffered since the Iran war began. The market is building on the recent gains this week even after U.S.-Iran negotiations over the weekend broke down, as investors remained optimistic that a deal between the two countries was still possible.
S&P 500 year to date
Greenlight's funds returned 6.5% in the first quarter, outperforming the S&P 500's 4.4% decline. Still, Einhorn said the firm has kept relatively low gross and net exposure, reflecting caution about valuations and the broader macro backdrop.
"Even the most cautious are investing with a Sammy Hagar inspired mentality: one foot on the brake and one on the gas," he said in the letter. "Nobody wants to miss the V- or even the checkmark-shaped recovery."
As the conflict began, Greenlight was already running with relatively low exposure, citing what it viewed as stretched valuations. Einhorn said Greenlight has made few adjustments, trading around index hedges and adding a long position in October oil futures. That bet has risen only modestly, as markets largely expect any supply disruption to be temporary.
Performance in the quarter was driven by gains in gold, Acadia Healthcare, DHT Holdings and Core Natural Resources, according to the letter. Greenlight also initiated a medium-sized position in Versant Media Group and smaller stakes in Crocs and SLM Corp.
Disclosure: Versant Media is the parent company of CNBC.
Acadia Healthcare Company, Inc. (NASDAQ:ACHC – Get Free Report) has earned an average recommendation of “Hold” from the sixteen research firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $21.1538.
Several analysts recently issued reports on the company. Barclays raised their target price on Acadia Healthcare from $14.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 3rd. UBS Group upped their price target on Acadia Healthcare from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Weiss Ratings reiterated a “sell (d)” rating on shares of Acadia Healthcare in a research report on Wednesday, January 21st. Jefferies Financial Group cut Acadia Healthcare to a “hold” rating in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada upped their target price on Acadia Healthcare from $17.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, February 26th.
Read Our Latest Analysis on Acadia Healthcare
Institutional Investors Weigh In On Acadia Healthcare Institutional investors and hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Acadia Healthcare by 54.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,404 shares of the company’s stock valued at $32,000 after purchasing an additional 497 shares in the last quarter. Wells Fargo & Company MN raised its stake in Acadia Healthcare by 208.9% in the fourth quarter. Wells Fargo & Company MN now owns 2,233 shares of the company’s stock worth $32,000 after buying an additional 1,510 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in Acadia Healthcare in the fourth quarter worth about $52,000. Hantz Financial Services Inc. lifted its holdings in Acadia Healthcare by 501.9% in the third quarter. Hantz Financial Services Inc. now owns 2,185 shares of the company’s stock worth $54,000 after buying an additional 1,822 shares during the period. Finally, GAMMA Investing LLC boosted its position in Acadia Healthcare by 124.7% during the 4th quarter. GAMMA Investing LLC now owns 4,862 shares of the company’s stock valued at $69,000 after acquiring an additional 2,698 shares in the last quarter.
Acadia Healthcare Trading Up 0.2% Shares of ACHC stock opened at $26.61 on Thursday. The business has a 50-day moving average price of $21.78 and a two-hundred day moving average price of $19.01. Acadia Healthcare has a 12-month low of $11.43 and a 12-month high of $28.48. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 1.27. The firm has a market cap of $2.45 billion, a P/E ratio of -2.18, a price-to-earnings-growth ratio of 8.97 and a beta of 0.71.
Acadia Healthcare (NASDAQ:ACHC – Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. Acadia Healthcare had a negative net margin of 33.29% and a positive return on equity of 6.53%. The firm had revenue of $821.46 million for the quarter, compared to the consensus estimate of $800.10 million. During the same period last year, the firm posted $0.64 earnings per share. The business’s revenue was up 6.1% compared to the same quarter last year. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. Equities analysts anticipate that Acadia Healthcare will post 3.38 EPS for the current fiscal year.
About Acadia Healthcare (Get Free Report)
Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.
Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.
Recommended Stories Five stocks we like better than Acadia Healthcare
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAppFolio (APPF) to Release Earnings on Thursday
NEXT HEADLINE »Vale (VALE) to Release Earnings on Thursday
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced the appointment of David Duckworth, former Chief Financial Officer of Acadia, as Interim Chief Financial Officer, effective May 1, 2026. Duckworth succeeds Todd Young, who is departing from the Company to pursue a CFO role at a private equity-backed animal health company. Young will remain with the Company through April 30, 2026, and will participate in the Company's firs.
Universal Health Services (UHS - Free Report) came out with quarterly earnings of $5.62 per share, beating the Zacks Consensus Estimate of $5.29 per share. This compares to earnings of $4.84 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +6.18%. A quarter ago, it was expected that this hospital and health facility operator would post earnings of $5.92 per share when it actually produced earnings of $5.88, delivering a surprise of -0.68%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Universal Health Services, which belongs to the Zacks Medical - Hospital industry, posted revenues of $4.5 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.00%. This compares to year-ago revenues of $4.1 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Universal Health Services shares have lost about 20% since the beginning of the year versus the S&P 500's gain of 4.7%.
What's Next for Universal Health Services?While Universal Health Services has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Universal Health Services was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $5.75 on $4.57 billion in revenues for the coming quarter and $23.40 on $18.53 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Hospital is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Acadia Healthcare (ACHC - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on April 29.
This provider of inpatient behavioral health care services is expected to post quarterly earnings of $0.28 per share in its upcoming report, which represents a year-over-year change of -30%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Acadia Healthcare's revenues are expected to be $824.24 million, up 7% from the year-ago quarter.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Results Revenue totaled $828.8 million, a 7.6% increase compared with the first quarter of 2025 Same-facility revenue increased 7.3% compared with the first quarter of 2025, including an increase in revenue per patient day of 5.6% and an increase in patient days of 1.6% Net income attributabl.
Acadia Healthcare (ACHC - Free Report) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.4 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +31.63%. A quarter ago, it was expected that this provider of inpatient behavioral health care services would post earnings of $0.03 per share when it actually produced earnings of $0.07, delivering a surprise of +133.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Acadia Healthcare, which belongs to the Zacks Medical - Hospital industry, posted revenues of $828.8 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.55%. This compares to year-ago revenues of $770.51 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia Healthcare shares have added about 94.4% since the beginning of the year versus the S&P 500's gain of 4.3%.
What's Next for Acadia Healthcare?While Acadia Healthcare has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia Healthcare was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.46 on $870.55 million in revenues for the coming quarter and $1.48 on $3.41 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Hospital is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Tenet Healthcare (THC - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on April 30.
This hospital operator is expected to post quarterly earnings of $4.21 per share in its upcoming report, which represents a year-over-year change of -3.4%. The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level.
Tenet Healthcare's revenues are expected to be $5.39 billion, up 3.2% from the year-ago quarter.
Acadia Healthcare Company, Inc. is downgraded to Sell due to persistent structural issues and a sharp valuation increase. Despite CEO change and capex cuts, ACHC faces a 200+ bps margin disadvantage from elevated insurance costs and rising claim frequency. ACHC's reliance on Medicaid (60.7% of revenue) is at risk from OBBBA, with reimbursement rates set to decline after 2028.
Key Takeaways Acadia Healthcare's Q1 EPS of 37 cents beat estimates as revenues rose 7.6% YoY to $828.8M.ACHC's growth was driven by higher patient days, admissions and a 14% Acute Inpatient revenue gain.ACHC raised its 2026 EBITDA outlook to $580-$615M and lifted EPS guidance despite rising expenses. Acadia Healthcare Company, Inc. (ACHC - Free Report) reported adjusted first-quarter earnings of 37 cents per share, which beat the Zacks Consensus Estimate of 28 cents. However, the bottom line declined 7.5% year over year.
Total revenues increased 7.6% year over year to $828.8 million. The top line beat the consensus mark of $824 million.
The better-than-expected quarterly results were driven by increased patient days and revenues per patient day, and higher admissions, which were partially offset by lower average length of stay and higher expenses.
ACHC’s Q1 OperationsACHC’s top line benefited most from its Acute Inpatient Psychiatric Facilities business, where revenues increased 14% year over year to $470.7 million and beat the Zacks Consensus Estimate by 6.4%. The metric benefited from higher volumes, aided by expanded capacity from both new construction and additions at existing facilities.
Specialty Treatment Facilities’ revenues declined 6.5% from the prior-year period to $128.1 million. Comprehensive Treatment Facilities’ revenues rose 2.5% year over year to $140.4 million, while Residential Treatment Facilities’ revenues increased 6.3% to $89.6 million.
Same-facility revenues of $813.4 million rose 7.3% year over year and beat the Zacks Consensus Estimate by 2%. The year-over-year improvement was driven by a 1.6% increase in patient days. Admissions grew 6.5% year over year. The average length of stay declined 4.6% year over year and missed the consensus estimate by 5.5%. Revenue per patient day increased 5.6% year over year.
In the overall facility, patient days improved 1.5% year over year, while admissions grew 7.8%. Revenue per patient day increased 5.9% year over year. The average length of stay declined 5.8% year over year.
Total expenses of $817.8 million rose from $757 million in the prior-year period due to higher salaries, wages and benefits, other operating expenses, supply costs and professional fees.
Total adjusted EBITDA rose 7.5% year over year to $144.2 million.
During the quarter, the company added 82 newly licensed beds, including 42 beds at existing facilities and 40 beds from newly constructed facilities, including a joint venture with Tufts Medicine.
Financial Update (as of March 31, 2026)Acadia Healthcare exited the first quarter with cash and cash equivalents of $158.5 million, which increased from $133.2 million at the 2025-end level. It had a leftover capacity of $564.8 million under its $1 billion revolving credit facility at the first-quarter end.
Total assets of $5.5 billion increased 0.3% from the figure at the end of 2025.
Long-term debt amounted to $2.5 billion, which rose from $0.9 billion as of Dec. 31, 2025. The current portion of long-term debt was $32.5 million.
Total equity of $2 billion increased from the 2025-end level of $1.9 billion.
Net cash provided by operations totaled $61.5 million in the first quarter of 2026 compared with $11.5 million in the prior-year comparable period.
Acadia Healthcare’s Share Repurchase UpdateThe company did not buy back shares in the first quarter of 2026.
Q2 Guidance by ACHCFor the second quarter of 2026, revenues are projected to be between $835 million and $850 million. Adjusted earnings per share (EPS) are predicted to be between 30 cents and 40 cents.
Adjusted EBITDA is estimated to be in the range of $142-$152 million.
Acadia Healthcare’s Revised 2026 OutlookRevenues are still projected to be in the range of $3.37 to $3.45 billion. Adjusted EBITDA is now estimated to be in the range of $580 to $615 million, up from the previous guidance range of $575 to $610 million. Adjusted EPS are now predicted to be between $1.35 and $1.60, up from the previous guidance range of $1.30 and $1.55.
Operating cash flows are now forecasted in the range of $285 to $325 million. Capital expenditures are expected to be in the range of $255-$280 million.
Management earlier estimated bed additions between 400 and 600 in 2026.
ACHC’s Zacks RankACHC currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
How Did Peers Perform?Several companies in the Medical space, including Molina Healthcare Inc. (MOH - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) , have already reported their financial results for the March quarter of 2026. Here’s how they had performed:
Molina Healthcare reported first-quarter 2026 adjusted earnings per share of $2.35, which beat the Zacks Consensus Estimate of $1.57. The bottom line declined 61.3% from the year-ago period's level. Revenues amounted to $10.8 billion, which decreased 3.1% year over year. The first-quarter performance was supported by lower medical care costs, partially offset by declining premiums, membership and investment income.
UnitedHealth reported first-quarter 2026 EPS of $7.23, which beat the Zacks Consensus Estimate of $6.46. The bottom line rose 0.4% year over year. Revenues rose 2% year over year to $111.7 billion. The quarterly earnings were aided by growth in commercial fee-based membership and the strength witnessed in Optum Rx. However, weakness in UnitedHealth’s Optum Health and declining risk-based membership partially offset the positives.
Elevance Health reported first-quarter 2026 adjusted earnings per share of $12.58, which surpassed the Zacks Consensus Estimate by 17.8%. The bottom line rose 5.1% year over year. Operating revenues advanced 1.5% year over year to $49.5 billion. The quarterly results benefited on the back of strong growth in premiums. Segment-wise, the Carelon division posted a robust revenue surge, aided by scaling risk-based services, while Health Benefits saw increased premium yields. However, Elevance Health’s upside was partly offset by a decline in overall medical membership and an elevated expense level.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
On May 15, 2026, 13D Management disclosed a new position in Acadia Healthcare (ACHC +4.10%), acquiring 294,000 shares in a trade estimated at $5.32 million based on quarterly average pricing.
What happenedAccording to a filing with the Securities and Exchange Commission dated May 15, 2026, 13D Management initiated a new position in Acadia Healthcare (ACHC +4.10%) by acquiring 294,000 shares. The estimated value of the trade, calculated using the average closing price for the first quarter of 2026, was $5.32 million. The quarter-end value of the holding was $6.88 million, reflecting the position’s valuation at the end of the period.
What else to knowThis was a new position for the fund, with Acadia Healthcare representing 10.7% of 13F reportable assets after the trade.Top five holdings after the filing:NYSE:TWLO: $7.64 million (11.85% of AUM)NASDAQ:VSAT: $7.55 million (11.7% of AUM)NASDAQ:ACHC: $6.88 million (10.7% of AUM)NYSE:PSO: $6.02 million (9.3% of AUM)NYSE:ALV: $5.87 million (9.1% of AUM)As of May 14, 2026, shares of Acadia Healthcare were priced at $26.80, roughly flat over the past year and well underperforming the S&P 500, which is instead up about 25%.Company overviewMetricValueRevenue (TTM)$3.37 billionNet Income (TTM)($1.10 billion)Price (as of market close May 14, 2026)$26.80Company snapshotAcadia Healthcare provides behavioral healthcare services, including inpatient psychiatric care, specialty treatment, residential treatment centers, and outpatient clinics across the United States and Puerto Rico.The firm operates a network-based model, generating revenue primarily from patient services at its owned and operated healthcare facilities.It serves individuals seeking mental health and addiction treatment, with primary customers including patients, families, and referring healthcare professionals.Acadia Healthcare is a leading provider of behavioral healthcare services, operating hundreds of facilities and thousands of beds across the United States and Puerto Rico. The company's scale and diversified service offerings position it as a key player in the mental health and addiction treatment sector. Acadia Healthcare's extensive facility network and focus on specialized care support its competitive advantage in addressing growing behavioral health needs.
What this transaction means for investorsAcadia Healthcare shares have badly lagged the broader market over the past year, but they surged over 60% last quarter alone, and 13D Management made the company one of its largest disclosed positions immediately after establishing the stake.
The timing is notable because Acadia’s underlying business trends have improved. First-quarter revenue climbed 7.6% to $828.8 million, while same-facility revenue rose 7.3%, helped by higher patient volumes and stronger pricing. Adjusted EBITDA increased to $144.2 million from $134.2 million a year earlier, prompting management to raise its full-year adjusted EBITDA and earnings guidance. CEO Debbie Osteen thanked disciplined execution, strong patient volumes, and continued operating efficiencies for the strong performance.
The company also continues expanding capacity. Acadia added 82 newly licensed beds during the quarter and now operates roughly 275 facilities with approximately 12,400 beds across 40 states and Puerto Rico. If management can keep this up, the stock’s recent underperformance could start to look more like an opportunity than a warning sign.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Twilio. The Motley Fool recommends Pearson Plc. The Motley Fool has a disclosure policy.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
It has been about a month since the last earnings report for Acadia Healthcare (ACHC - Free Report) . Shares have lost about 8.2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Acadia Healthcare due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Acadia Healthcare Company, Inc. before we dive into how investors and analysts have reacted as of late.
Acadia Healthcare Q1 Earnings Beat Estimates on Rising Patient Days
Acadia Healthcare reported adjusted first-quarter earnings of 37 cents per share, which beat the Zacks Consensus Estimate of 28 cents. However, the bottom line declined 7.5% year over year.
Total revenues increased 7.6% year over year to $828.8 million. The top line beat the consensus mark of $824 million.
The better-than-expected quarterly results were driven by increased patient days and revenues per patient day, and higher admissions, which were partially offset by lower average length of stay and higher expenses.
ACHC’s Q1 OperationsACHC’s top line benefited most from its Acute Inpatient Psychiatric Facilities business, where revenues increased 14% year over year to $470.7 million and beat the Zacks Consensus Estimate by 6.4%. The metric benefited from higher volumes, aided by expanded capacity from both new construction and additions at existing facilities.
Specialty Treatment Facilities’ revenues declined 6.5% from the prior-year period to $128.1 million. Comprehensive Treatment Facilities’ revenues rose 2.5% year over year to $140.4 million, while Residential Treatment Facilities’ revenues increased 6.3% to $89.6 million.
Same-facility revenues of $813.4 million rose 7.3% year over year and beat the Zacks Consensus Estimate by 2%. The year-over-year improvement was driven by a 1.6% increase in patient days. Admissions grew 6.5% year over year. The average length of stay declined 4.6% year over year and missed the consensus estimate by 5.5%. Revenue per patient day increased 5.6% year over year.
In the overall facility, patient days improved 1.5% year over year, while admissions grew 7.8%. Revenue per patient day increased 5.9% year over year. The average length of stay declined 5.8% year over year.
Total expenses of $817.8 million rose from $757 million in the prior-year period due to higher salaries, wages and benefits, other operating expenses, supply costs and professional fees.
Total adjusted EBITDA rose 7.5% year over year to $144.2 million.
During the quarter, the company added 82 newly licensed beds, including 42 beds at existing facilities and 40 beds from newly constructed facilities, including a joint venture with Tufts Medicine.
Financial Update (as of March 31, 2026)Acadia Healthcare exited the first quarter with cash and cash equivalents of $158.5 million, which increased from $133.2 million at the 2025-end level. It had a leftover capacity of $564.8 million under its $1 billion revolving credit facility at the first-quarter end.
Total assets of $5.5 billion increased 0.3% from the figure at the end of 2025.
Long-term debt amounted to $2.5 billion, which rose from $0.9 billion as of Dec. 31, 2025. The current portion of long-term debt was $32.5 million.
Total equity of $2 billion increased from the 2025-end level of $1.9 billion.
Net cash provided by operations totaled $61.5 million in the first quarter of 2026 compared with $11.5 million in the prior-year comparable period.
Acadia Healthcare’s Share Repurchase UpdateThe company did not buy back shares in the first quarter of 2026.
Q2 Guidance by ACHCFor the second quarter of 2026, revenues are projected to be between $835 million and $850 million. Adjusted earnings per share (EPS) are predicted to be between 30 cents and 40 cents.
Adjusted EBITDA is estimated to be in the range of $142-$152 million.
Acadia Healthcare’s Revised 2026 OutlookRevenues are still projected to be in the range of $3.37 to $3.45 billion. Adjusted EBITDA is now estimated to be in the range of $580 to $615 million, up from the previous guidance range of $575 to $610 million. Adjusted EPS are now predicted to be between $1.35 and $1.60, up from the previous guidance range of $1.30 and $1.55.
Operating cash flows are now forecasted in the range of $285 to $325 million. Capital expenditures are expected to be in the range of $255-$280 million.
Management earlier estimated bed additions between 400 and 600 in 2026.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -27.8% due to these changes.
VGM ScoresCurrently, Acadia Healthcare has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Acadia Healthcare has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was “Welcome back, my friends to the show that never ends.” On cue, the never-say-die stock market shook off early worries and all the major indices closed higher on Tuesday. Like the proverbial broken record, the S&P 500 printed yet another all-time high, closing the session at 7,609, up another 0.13%, and for the first time closing over 7,600. In contrast, the Nasdaq barely closed higher, up 0.03% at 27,093. The Dow Jones Industrials, which started the day lower, then rallied to close at 51,307, up 0.45%, and the small-cap-heavy Russell 2000 joined the party, closing at 2,931, up 0.90%.
Treasury Bonds: Yields were lower across the entire Treasury curve yesterday, as investors returned to U.S. sovereign debt. The rally was primarily fueled by investors’ heightened focus on U.S.-Iran peace negotiations and a partial ceasefire in the Middle East. These developments meaningfully eased concerns about global inflationary pressures and the risk of sharp oil-price spikes. Yet, even as the broader equity market continued its advance, lingering geopolitical uncertainties surrounding the U.S.-Iran deadlock prompted a defensive shift in capital toward the relative safety of U.S. government debt. The 30-year-long bond closed the day at 4.97%, while the 10-year note closed at 4.45%.
Oil and Gas: Prices were higher across the energy complex as the song remains the same, amid uncertainty over U.S.-Iran peace negotiations and stalled efforts to reopen the Strait of Hormuz. Prices rallied after reports that Iran was reviewing the latest U.S. peace proposal, but as usual with Iran, progress remained stalled, and Hezbollah rejected a partial ceasefire with Israel. Brent Crude closed at $95.79, up 0.85%, while the last trade for West Texas Intermediate. came in at $93.29, up 1.33%. Natural gas closed essentially flat at $3.16.
Gold: After a solid day for the debt and equity markets, precious metals finished the session modestly higher. Again, across almost every asset class, the shifting narrative on the war with Iran swings the major indices one way or the other. Gold closed up a modest 0.07% at 4,478, while Silver was last seen at $75, up 0.35%.
Crypto: Cryptocurrency markets suffered a sharp selloff on Tuesday, as Bitcoin plunged below $67,000, its lowest level since April. The steep drop triggered more than $1.2 billion in long liquidations across the market, pulling Ethereum, major altcoins, and crypto-related stocks lower. At 1 PM EDT, Bitcoin is trading at $66,934, down 4.9% in the last 24 hours, while Ethereum was quoted at $1,823.
24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock.
Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Wednesday, June 3, 2026.
Upgrades: Acadia Healthcare Company (NASDAQ: ACHC | ACHC Price Prediction) was upgraded to Buy from Hold at Jefferies, which lifted the price target to $30 from $24.50. SSR Mining (NASDAQ: SSRM) was upgraded to Outperform from Sector Perform at RBC Capital, which trimmed the target price for the stock to $40 from $45. Yum! Brands (NYSE: YUM) was upgraded to Overweight from Equal Weight at Morgan Stanley, with the target price raised to $185 from $180. Downgrades: Chipotle Mexican Grill (NYSE: CMG) was cut to Equal Weight from Overweight at Morgan Stanley, which lowered the price target for the shares to $37 from $49. Conagra Brands (NYSE: CAG) was cut to Underperform from Market Perform at Bernstein, which trimmed the target price to $12 from $16. Dollar General (NYSE: DG) was downgraded to Hold from Buy at Freedom Broker, which raised the price target for the small-town retail giant to $140 from $95. MGM Resorts International (NYSE: MGM) was downgraded to Hold from Buy at CBRE, with a $50 target price. Initiations: Boyd Gaming (NYSE: BYD) was initiated with a Buy rating at Texas Capital, which has a $106 target price for the shares. BridgeBio Pharma (NASDAQ: BBIO) was started with a Buy rating at Canaccord with a $104 price target. Omnicom Group (NYSE: OMC) was initiated with a Buy rating at Goldman Sachs, with a $146 target price objective.
Viking Holdings (NYSE: VIK) was started with an Outperform rating at Bernstein, with a $120 target price.
